| Pharmaceutical Information |
| Drug Name |
Enfuvirtide |
| Drug ID |
BADD_D00771 |
| Description |
Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells. |
| Indications and Usage |
Enfuvirtide is an antiretroviral drug used in combination therapy for the treatment of HIV-1/AIDS. |
| Marketing Status |
approved; investigational |
| ATC Code |
J05AX07 |
| DrugBank ID |
DB00109
|
| KEGG ID |
D02499
|
| MeSH ID |
D000077560
|
| PubChem ID |
16130199
|
| TTD Drug ID |
D06GBQ
|
| NDC Product Code |
12869-380; 0004-0381 |
| UNII |
19OWO1T3ZE
|
| Synonyms |
Enfuvirtide | Pentafuside | DP 178 | DP178 | DP-178 | Fuzeon | T20 Peptide | Peptide T20 | T20, Peptide |
|
| Chemical Information |
| Molecular Formula |
C204H301N51O64 |
| CAS Registry Number |
159519-65-0 |
| SMILES |
CCC(C)C(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)O)C(=O)NC(CO)C(=O)NC(CCC(=O)N)C(=O)NC(CC
(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCCCN)C(=O)NC(C
C(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CCC(=O)N)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC
(CC(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC(C)C)C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(CC
1=CNC2=CC=CC=C21)C(=O)NC(C)C(=O)NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC3=CNC4=CC=CC=C43)
C(=O)NC(CC(=O)N)C(=O)NC(CC5=CNC6=CC=CC=C65)C(=O)NC(CC7=CC=CC=C7)C(=O)N)NC(=O)C(C
C(C)C)NC(=O)C(CO)NC(=O)C(CC8=CN=CN8)NC(=O)C(C(C)CC)NC(=O)C(CC(C)C)NC(=O)C(CO)NC(
=O)C(C(C)O)NC(=O)C(CC9=CC=C(C=C9)O)NC(=O)C |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
